Allarity Therapeutics, Inc. (ALLR)
- Previous Close
1.5400 - Open
1.4800 - Bid 1.1200 x 200
- Ask 1.7600 x 200
- Day's Range
1.3500 - 1.5785 - 52 Week Range
1.2800 - 442.4000 - Volume
447,894 - Avg. Volume
482,863 - Market Cap (intraday)
2.705M - Beta (5Y Monthly) 0.24
- PE Ratio (TTM)
-- - EPS (TTM)
-205.2000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.
www.allarity.comRecent News: ALLR
Performance Overview: ALLR
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALLR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALLR
Valuation Measures
Market Cap
2.72M
Enterprise Value
5.60M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.50
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-81.08%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-20.42M
Diluted EPS (ttm)
-205.2000
Balance Sheet and Cash Flow
Total Cash (mrq)
222k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-5.47M
Research Analysis: ALLR
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell